| Trial ID: | L0854 |
| Source ID: | IRCT2015122525641N2
|
| Associated Drug: |
Curcumin
|
| Title: |
Effect of Curcumin in treatment of Non-Alcoholic Fatty Liver Disease: A Randomized Double-blind Clinical Trial Including Placebo
|
| Acronym: |
--
|
| Status: |
Not Recruiting
|
| Study Results: |
No Results Available
|
| Results: |
--
|
| Conditions: |
Fatty Liver. <br>Fatty (change of) liver, not elsewhere classified;Fatty (change of) liver, not elsewhere classified
|
| Interventions: |
Intervention 1: Curcumin, 500 mg oral Capsule,2 times a day for 8 weeks. Intervention 2: Placebo, 500mg oral capsule, twice a day for 8 weeks.;Treatment - Drugs;Placebo;Curcumin, 500 mg oral Capsule,2 times a day for 8 weeks;Placebo, 500mg oral capsule, t
|
| Outcome Measures: |
The accumulation of liver fat. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Color Doppler Ultrasonography.Portal vein diameter. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Color Doppler Ultrasonography.;Hepatic blood flow velocity. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Color Doppler Ultrasonography.;AST. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;ALT. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;HDL. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;Total Cholesetrol. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;LDL. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;TG. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;Uric Acid. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;FBS. Timepoint: Before the intervention, 8 weeks later at the end of the intervention. Method of measurement: Blood test.;HbA1C. Timepoint: Before the intervention,8 weeks later at the end of the intervention. Method of measurement: Blood test.
|
| Sponsor/Collaborators: |
Vice chancellor for research of Baqiyatallah University of Medical Science
|
| Gender: |
All
|
| Age: |
18 years139 years
|
| Phases: |
Phase 2/Phase 3
|
| Enrollment: |
100
|
| Study Type: |
interventional
|
| Study Designs: |
Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: It is a double-blind clinical trail in which neither patients nor analysis technician have no information about the kind o
|
| Start Date: |
16/01/2016
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
22 February 2018
|
| Locations: |
Iran (Islamic Republic of)
|
| URL: |
http://en.irct.ir/trial/21399
|
